Chronic hypertension complicates 3%-5% of pregnancies and gestational hypertension occurs in 6% of pregnancies. Preeclampsia complicates 25% of the pregnancies with chronic hypertension, and approximately 15%-45% of the patients with gestational hypertension will develop preeclampsia, a dangerous condition that harms the maternal and fetal safety. Antihypertensive medication is used to treat severe hypertension to prevent serious maternal and fetal complications, but there is no consensus on when and how to treat mild-to-moderate hypertension in pregnancy. This article reviews the usage, effect and safety of first, second and third line antihypertensive drugs for mild-tomoderate hypertension in pregnancy. 
Hypertension in pregnancy
For the hypertension diagnosis, blood pressure (BP) must be elevated on at least two occasions and measurements should be made with the woman seated and using the appropriate cuff size. Late in the second trimester and the third trimester, venous return may be obstructed by the gravid uterus and, if supine, blood pressure should be taken with the woman lying on her side. Chronic hypertension is diagnosed before pregnancy or in the first 20 weeks of gestation, or persists more than 42 days after delivery, complicating 3%-5% of pregnancies [1] . In gestational hypertension, occurring in 6% of pregnancies, blood pressure is established after the week 20 of pregnancy, and is not associated to proteinuria or other systemic features of preeclampsia, with normalization during the 12 weeks following delivery. Approximately 15%-45% of the patients with gestational hypertension will develop preeclampsia, and is more likely with earlier presentation, previous hypertensive pregnancy and higher blood pressure [2, 3] . The effect of antihypertensive drugs is different in these conditions, which must be considered when interpreting randomized trials of the treatment of hypertension in pregnancy.
Preeclampsia is more dangerous than chronic hypertension and gestational hypertension, and is characterized by hypertension and proteinuria (0.3 g/24 hours). Eclampsia is described as the appearance of convulsions associated with the signs of preeclampsia, and not caused by epilepsy or other convulsive disorders. Preeclampsia superimposed on chronic hypertension is defined as a condition of hypertension with onset of proteinuria, complicating 25% of the pregnancies with chronic hypertension [4] .
Physiological adaptations in pregnancy and hypertension
Early in the first trimester there is a fall in blood pressure caused by active vasodilatation through local mediators. This reduction primarily affects the diastolic pressure and a drop of 10 mm Hg is usual by 13-20 weeks of gestation.
Blood pressure continues to fall until 22-24 weeks when a nadir is reached. After this, there is a gradual increase in blood pressure until a term when pre-pregnancy levels are attained. Immediately after delivery blood pressure usually falls, then increases over the first five postpartum days. Even women whose blood pressure was normal during pregnancy may experience transient hypertension in the early postpartum period, reflecting a degree of vasomotor instability [5, 6] . tension have a 10% to 30% increased risk of developing preeclampsia [7] . If preeclampsia does not occur, the course of mild and moderate essential hypertension is benign, and it is uncertain whether antihypertensive treatment improves the outcome of pregnancy. Prevention of preeclampsia is desirable, but either specific BP targets or antihypertensive agents modify the risk [8] . The hyper- Preeclampsia is a progressive systemic disease due to inadequate trophoblastic invasion of the spiral arterioles that occurs in 5%-8% of all pregnancies.
It is associated with significant maternal and fetal morbidity and mortality.
In preeclampsia hypertension is due to [10] in pregnancy is associated with lower maternal risk [8] . Those with hypertensive encephalopathy, hemorrhage or eclampsia require treatment with parenteral agents to lower mean arterial pressure by 25% over minutes to hours and then to further lower BP to 160/100 mm Hg over subsequent hours [10] , avoiding hypotension because of fetal distress.
Treatment of hypertension
Lower doses should be initiated in preeclampsia, because of volume depletion.
The question has been raised whether treatment is necessary in mild- [12] . Clinical trials indicate non-consistent data concerning antihypertensive treatment on antenatal rate of hospitalization, proteinuria at delivery and neonatal respiratory distress syndrome, preeclampsia, fetal neonatal death, preterm labor or intra-uterine growth restriction (IUGR) [13, 14] . mm Hg [18] . In women with renal dysfunction, it may be reasonable to choose a slightly lower threshold for treatment [4] . ization and proteinuria at delivery [19] .
Antihypertensive treatments for mild-tomoderate hypertension are beneficial for the mother, but pregnancy outcome has been found to be similar or even worse [8, 17] . 
Antihypertensive drugs
One concern is that hypertension or There is extensively experience with the drug and long-term follow-up data regarding children whose mothers received methyldopa during pregnancy with proven maternal and fetal safety [22, 26] . In a follow-up study of a large clinical trial on the effectiveness of methyldopa versus no treatment, no differences were found in the functional development of children at 4 and 7.5 years of age [27, 28] . During the long term treatment, the drug does not alter cardiac output or blood flow to the uterus or kidneys [29] . Also fetal heart rate patterns were not significantly changed during the treatment [30] . BP control is [33] . However, in a recent meta-analysis of published data from randomized trials, the presence of intrauterine growth retardation appeared not to be related to the antihypertensive used [34] . A recent meta-analysis of intravenous hydralazine usage in severe hypertension in pregnancy concluded that parenteral labetalol or oral nifedipine were preferable first line agents in accordance with association of intravenous hydralazine with more maternal and perinatal adverse effects, such as maternal hypotension, maternal oliguria, cesarean section, placental abruption, adverse effects on fetal heart rate and low Apgar scores at one minute [36, 56] .
Isosorbide nitrate, a nitric oxid (NO) donor, has been investigated in a small study of gestational hypertensive and preeclamptic pregnant patients. It was found that cerebral perfusion pressure is unaltered by isosorbide dinitrate, despite significant changes in maternal BP, thus decreasing the risk for ischemia and infarction when BP is lowered [57] . 
Management of hypertension postpartum
In the postpartum period, previously 
Summary
For severe hypertension, antihypertensive medication is used to prevent serious maternal and fetal complications.
However, there is no consensus on when to treat mild-to-moderate hypertension.
Although treatment could benefit the mother, it carries potential risks to the fetus from impaired uteroplacental perfusion and fetal exposure to medication. tive health outcomes are needed [14] .
As women in developed countries delay childbirth, the impact of chronic hypertension will increase. Clinicians known and should be evaluated [82] .
The ideal drug for the treatment of pregnancy hypertension should be rapidly effective and long acting, with minimal side effects to the mother, and it should not compromise the fetus either directly or by a reduction in placental perfusion.
The objective of treating hypertension in pregnancy is to protect the women from dangerously high blood pressure and to permit continuation of the pregnancy, fetal growth and maturation.
